Skip to content

Operating Income at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
CG Oncology logo
CG OncologyCGON
-$66.39M-57.3%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$57.99M-66.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.93M+27.9%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%

Other financials

Income statement

See full
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s operating income?
Oric Pharmaceuticals, Inc. (ORIC) reported operating income of -$39.62M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s operating income changed year-over-year?
Oric Pharmaceuticals, Inc.'s operating income decreased by 21.1% year-over-year, from -$32.72M to -$39.62M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s operating income?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s operating income has grown at a 16.0% compound annual growth rate (CAGR), from -$78.87M to -$143M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.